$XWEL
XWELL Inc

2022 Q1 Form 10-Q Financial Statement

#000155837022008969 Filed on May 16, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $24.05M $8.512M
YoY Change 182.52% 10.26%
Cost Of Revenue $15.05M $4.159M
YoY Change 261.79% -41.99%
Gross Profit $9.001M $4.353M
YoY Change 106.78% 691.45%
Gross Profit Margin 37.43% 51.14%
Selling, General & Admin $10.19M $4.508M
YoY Change 126.0% 39.57%
% of Gross Profit 113.19% 103.56%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $1.264M $744.0K
YoY Change 69.89% -41.42%
% of Gross Profit 14.04% 17.09%
Operating Expenses $10.19M $4.508M
YoY Change 126.0% 0.18%
Operating Profit -$2.451M -$921.0K
YoY Change 166.12% -76.68%
Interest Expense -$266.0K $110.0K
YoY Change -341.82% -110.38%
% of Operating Profit
Other Income/Expense, Net -$318.0K $102.0K
YoY Change -411.76% -129.14%
Pretax Income -$2.762M -$807.0K
YoY Change 242.26% -92.47%
Income Tax $0.00 $1.000K
% Of Pretax Income
Net Earnings -$4.283M -$1.056M
YoY Change 305.59% -90.15%
Net Earnings / Revenue -17.81% -12.41%
Basic Earnings Per Share -$0.04 -$0.01
Diluted Earnings Per Share -$0.04 -$0.01
COMMON SHARES
Basic Shares Outstanding 101.6M 101.1M
Diluted Shares Outstanding 101.6M 101.1M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $82.99M $102.6M
YoY Change -19.11% 2530.77%
Cash & Equivalents $82.99M $103.4M
Short-Term Investments
Other Short-Term Assets $1.027M $1.000M
YoY Change 2.7% 0.0%
Inventory $2.522M $1.200M
Prepaid Expenses
Receivables $1.924M $3.000M
Other Receivables $0.00 $0.00
Total Short-Term Assets $88.46M $107.8M
YoY Change -17.94% 1896.3%
LONG-TERM ASSETS
Property, Plant & Equipment $8.273M $7.600M
YoY Change 8.86% -51.59%
Goodwill $4.260M
YoY Change
Intangibles $5.205M
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.541M $3.700M
YoY Change -31.32% 94.74%
Total Long-Term Assets $25.28M $12.02M
YoY Change 110.27% -49.5%
TOTAL ASSETS
Total Short-Term Assets $88.46M $107.8M
Total Long-Term Assets $25.28M $12.02M
Total Assets $113.7M $119.8M
YoY Change -5.08% 310.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $12.90M $7.000M
YoY Change 84.29% -39.13%
Accrued Expenses $2.833M $2.800M
YoY Change 1.18% -24.32%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $1.433M $4.000M
YoY Change -64.18%
Total Short-Term Liabilities $18.65M $13.80M
YoY Change 35.13% -14.29%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $1.600M
YoY Change -100.0% -67.35%
Other Long-Term Liabilities $7.301M $6.400M
YoY Change 14.08% -46.22%
Total Long-Term Liabilities $7.301M $8.000M
YoY Change -8.74% -52.38%
TOTAL LIABILITIES
Total Short-Term Liabilities $18.65M $13.80M
Total Long-Term Liabilities $7.301M $8.000M
Total Liabilities $25.95M $25.80M
YoY Change 0.58% -29.51%
SHAREHOLDERS EQUITY
Retained Earnings -$399.6M
YoY Change
Common Stock $951.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $79.69M $94.00M
YoY Change
Total Liabilities & Shareholders Equity $113.7M $119.8M
YoY Change -5.06% 310.27%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$4.283M -$1.056M
YoY Change 305.59% -90.15%
Depreciation, Depletion And Amortization $1.264M $744.0K
YoY Change 69.89% -41.42%
Cash From Operating Activities -$1.774M -$3.498M
YoY Change -49.29% -0.63%
INVESTING ACTIVITIES
Capital Expenditures $1.659M $986.0K
YoY Change 68.26% -270.0%
Acquisitions $4.853M
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$6.779M -$986.0K
YoY Change 587.53% 70.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $11.10M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -13.94M 17.34M
YoY Change -180.41% 199.48%
NET CHANGE
Cash From Operating Activities -1.774M -3.498M
Cash From Investing Activities -6.779M -986.0K
Cash From Financing Activities -13.94M 17.34M
Net Change In Cash -22.52M 12.85M
YoY Change -275.25% 660.24%
FREE CASH FLOW
Cash From Operating Activities -$1.774M -$3.498M
Capital Expenditures $1.659M $986.0K
Free Cash Flow -$3.433M -$4.484M
YoY Change -23.44% 52.52%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
101601913
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
101058500
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001410428
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
101269349
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
95071210
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-34785
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
XpresSpa Group, Inc.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-4988129
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
254 West 31st Street
CY2022Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
11th Floor
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
New York
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10001
CY2022Q1 dei City Area Code
CityAreaCode
212
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
309-7549
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.01 per share
CY2022Q1 dei Trading Symbol
TradingSymbol
XSPA
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
95360271
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
82990000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
105506000
CY2022Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1924000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
615000
CY2022Q1 us-gaap Inventory Net
InventoryNet
2522000
CY2021Q4 us-gaap Inventory Net
InventoryNet
1763000
CY2022Q1 us-gaap Other Assets Current
OtherAssetsCurrent
1027000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1095000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
88463000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
108979000
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
751000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
751000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8273000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6658000
CY2022Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
5205000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
3732000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4245000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4336000
CY2022Q1 us-gaap Goodwill
Goodwill
4260000
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2541000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2810000
CY2022Q1 us-gaap Assets
Assets
113738000
CY2021Q4 us-gaap Assets
Assets
127266000
CY2022Q1 xspa Accounts Payable Accrued Liabilities And Other Current
AccountsPayableAccruedLiabilitiesAndOtherCurrent
12918000
CY2021Q4 xspa Accounts Payable Accrued Liabilities And Other Current
AccountsPayableAccruedLiabilitiesAndOtherCurrent
12958000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2833000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2736000
CY2022Q1 us-gaap Deferred Revenue
DeferredRevenue
1464000
CY2021Q4 us-gaap Deferred Revenue
DeferredRevenue
549000
CY2022Q1 us-gaap Unsecured Debt Current
UnsecuredDebtCurrent
1433000
CY2021Q4 us-gaap Unsecured Debt Current
UnsecuredDebtCurrent
3584000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
18648000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
19827000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7301000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7504000
CY2022Q1 us-gaap Liabilities
Liabilities
25949000
CY2021Q4 us-gaap Liabilities
Liabilities
27331000
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
95071210
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
101269349
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
951000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
1013000
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
478649000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
487306000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-399558000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-395275000
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-353000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-312000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
79689000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
92732000
CY2022Q1 us-gaap Minority Interest
MinorityInterest
8100000
CY2021Q4 us-gaap Minority Interest
MinorityInterest
7203000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
87789000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
99935000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
113738000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
127266000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
24048000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8512000
CY2022Q1 us-gaap Cost Direct Labor
CostDirectLabor
5462000
CY2021Q1 us-gaap Cost Direct Labor
CostDirectLabor
1215000
CY2022Q1 xspa Cost Of Occupancy
CostOfOccupancy
1068000
CY2021Q1 xspa Cost Of Occupancy
CostOfOccupancy
481000
CY2022Q1 xspa Products And Other Operating Costs
ProductsAndOtherOperatingCosts
8517000
CY2021Q1 xspa Products And Other Operating Costs
ProductsAndOtherOperatingCosts
2463000
CY2022Q1 us-gaap Cost Of Revenue
CostOfRevenue
15047000
CY2021Q1 us-gaap Cost Of Revenue
CostOfRevenue
4159000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1264000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
744000
CY2021Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
22000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-2762000
CY2021Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
12000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-318000
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
10188000
CY2021Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4508000
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
26499000
CY2021Q1 us-gaap Costs And Expenses
CostsAndExpenses
9433000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2451000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-921000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
102000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2762000
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-807000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-2762000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-808000
CY2022Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
1521000
CY2021Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
248000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-4283000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-1056000
CY2022Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
7000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-808000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-41000
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-16000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2803000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-824000
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
101601913
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
101058500
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
101601913
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
101058500
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
99935000
CY2022Q1 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
906000
CY2022Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
73000
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
1543000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-2762000
CY2022Q1 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
11095000
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-41000
CY2022Q1 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
824000
CY2022Q1 us-gaap Noncontrolling Interest Decrease From Deconsolidation
NoncontrollingInterestDecreaseFromDeconsolidation
200000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
87789000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
80371000
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
1005000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-808000
CY2021Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-16000
CY2021Q1 us-gaap Noncontrolling Interest Decrease From Deconsolidation
NoncontrollingInterestDecreaseFromDeconsolidation
333000
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
97892000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-2762000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-808000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1264000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
744000
CY2021Q1 xspa Impairment Of Long Lived Assets
ImpairmentOfLongLivedAssets
22000
CY2022Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
398000
CY2021Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
224000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1543000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1005000
CY2022Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-273000
CY2021Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
99000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1774000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3498000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
90502000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
83741000
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
759000
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
508000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
906000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3019000
CY2022Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
192000
CY2022Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-82000
CY2021Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-91000
CY2022Q1 xspa Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-1612000
CY2021Q1 xspa Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-825000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
513000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-325000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1659000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
986000
CY2022Q1 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
4853000
CY2022Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
267000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6779000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-986000
CY2021Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
17007000
CY2022Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
11095000
CY2022Q1 us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
200000
CY2021Q1 us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
333000
CY2022Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
73000
CY2022Q1 xspa Repayment Of Paycheck Protection Program
RepaymentOfPaycheckProtectionProgram
2151000
CY2022Q1 us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
824000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-13943000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
17340000
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-20000
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-8000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-22516000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
12848000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
106257000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
103350000
CY2022Q1 us-gaap Interest Paid
InterestPaid
7000
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
765000
CY2022Q1 us-gaap Business Combination Consideration Transferred Equity Interests Issued And Issuable
BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
906000
CY2022Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 1. General</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">XpresSpa Group, Inc. (“XpresSpa Group” or the “Company”) is a leading global travel health and wellness services holding company. XpresSpa Group currently has </span><span style="font-size:10pt;">four</span><span style="font-size:10pt;"> reportable operating segments: XpresSpa</span><sup style="font-size:5.62pt;line-height:100%;top:0pt;vertical-align:top;background:#ffffff;">®</sup><span style="font-size:10pt;">, Xpres</span><span style="font-size:10pt;">Test</span><sup style="font-size:5.62pt;line-height:100%;top:0pt;vertical-align:top;background:#ffffff;">®</sup><span style="font-size:10pt;">, Treat</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;background:#ffffff;">™</sup><span style="font-size:10pt;">, and HyperPointe which was acquired in January 2022.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">XpresSpa Group’s subsidiary, XpresSpa Holdings, LLC (“XpresSpa”) has been a global airport retailer of spa services through its XpresSpa spa locations, offering travelers premium spa services, including massage, nail and skin care, as well as spa and travel products (“XpresSpa”). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Through XpresSpa Group’s XpresTest, Inc. subsidiary (“XpresTest”), the company launched XpresCheck Wellness Centers, also in airports. XpresCheck offers COVID-19 and other medical diagnostic testing services to the traveling public, as well as airline, airport and concessionaire employees, and TSA and U.S. Customs and Border Protection agents. XpresTest has entered into managed services agreements (“MSAs”) with professional medical services companies that provide health care services to patients. The medical services companies pay XpresTest a monthly fee to operate in the XpresCheck Wellness Centers. Under the terms of the MSAs, XpresTest provides office space, equipment, supplies, non-licensed staff, and management services in return for a management fee. Effective July 1, 2021, the Company determined that the PLLCs are VIEs due to their equity holders having sufficient capital at risk, and the Company having a variable interest and a primary beneficiary in the PLLCs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The third segment is Treat, which is operating through XpresSpa Group’s subsidiary Treat, Inc. (“Treat”). Treat is a travel health and wellness brand that provides access to health and wellness services for travelers at on-site centers (currently located in JFK International Airport and  Phoenix Sky Harbor International Airport and opening later this year in Salt Lake City International Airport).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s HyperPointe segment, which the Company acquired in January 2022 (<i style="font-style:italic;">see Note 7.</i> <i style="font-style:italic;">Acquisition of HyperPointe</i>), provides a broad range of service and support options for our customers, including technical support services and advanced services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basis of Presentation and Principles of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and the instructions to Article 8-03 of Regulation S-X, and should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, as amended. The condensed consolidated balance sheet as of December 31, 2021 was derived from the audited annual financial statements but does not include all information required by GAAP for annual financial statements. The financial statements include the accounts of the Company, all entities that are wholly owned by the Company, and all entities in which the Company has a controlling financial interest as well as variable interest entities in which we are the primary beneficiaries. All adjustments that, in the opinion of management, are necessary for a fair presentation for the periods presented have been reflected by the Company. Such adjustments are of a normal, recurring nature. The results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results that may be expected for the entire fiscal year or for any other interim period. All significant intercompany balances and transactions have been eliminated in consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">Recent Developments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-line:none;">XpresCheck Wellness Centers</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">XpresCheck’s business has MSAs with state licensed physicians and nurse practitioners, under which we administer COVID-19 testing options, including a Polymerase Chain Reaction (PCR) test and a rapid PCR test. As of the date of this report, there are 15 operating XpresCheck locations operating in 12 airports, including following locations opened since December 31, 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;"> In February 2022, a second XpresCheck Wellness Center opened at Denver International Airport, pre-security in the Great Hall. It contains </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">six</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> separate testing rooms to provide diagnostic COVID-19 testing.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In March 2022, we opened an XpresCheck Wellness Center in Orlando International Airport, pre-security, in the South Walk area of the Main Terminal. It contains </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> separate testing rooms to provide diagnostic COVID-19 testing.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During 2021, XpresCheck initiated a $2,001 eight-week pilot program with the Centers for Disease Control and Prevention (CDC) in collaboration with Concentric by Ginkgo. Under this program, XpresCheck is conducting biosurveillance monitoring at four major U.S. airports (JFK International Airport, Newark Liberty International Airport, San Francisco International Airport, and Hartsfield-Jackson Atlanta International Airport) aimed at identifying existing and new SARS-CoV-2 variants. On January 31, 2022, the Company announced the extension of the program, bringing the total contract to $5,534. Approximately $1,396 and $1,368 of the full $5,534 amount was recognized during the first quarter of 2022 and the fourth quarter of 2021, respectively. The Company anticipates that the remaining $2,770 of the full $5,534 amount will be realized in the second and third quarters of 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">XpresSpa</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There are currently nineteen operating XpresSpa domestic locations (including two franchise location in Austin-Bergstrom International Airport) and the Company expects to re-open four additional domestic locations in the near-term. A significant number of the domestic XpresSpa locations are operating approximately eight hours per day during the busiest hours (compared to up to sixteen hours per day pre-pandemic) improving labor productivity. Additionally, XpresSpa implemented a price increase in mid-October 2021 in its efforts to return to profitability. As passenger airport volumes improve, the Company will continue to review operating hours to optimize revenue opportunity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the fourth quarter of 2021, the Company began testing several new services to take advantage of a growing interest in non-traditional spa services and expansion of our retail offering to align more closely with the services the Company provides. The company is evaluating the success of these new initiatives at each airport on an on-going basis and will incorporate changes to our approach as more of the portfolio is reactivated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company also has six international locations operating, including three XpresSpa locations in Dubai International Airport in the United Arab Emirates and three XpresSpa locations in Schiphol Amsterdam Airport in the Netherlands. The Company also signed for an additional five locations at Istanbul Airport and expects to open the first store during the summer of 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Treat</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Treat is the Company’s new travel, health and wellness brand transforming the way we access care through a suite of health and wellness services supported by an integrated digital platform and a relevant retail offering to the traveling public.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Treat’s on-site centers (currently located in JFK International Airport and in Phoenix Sky Harbor International Airport and opening later this year in Salt Lake City International Airport) provide access to health and wellness services for travelers. The Treat teams provide travel-related diagnostic testing for virus, cold, flu and other illnesses as well as hydration therapy, IV drips, and vitamin injections. Travelers can purchase time blocks to use the Company’s wellness rooms to engage in </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">interactive services like self-guided yoga, meditation and low impact weight exercises or to relax and unplug from the hectic pace of the airport and renew themselves before or after their trip.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Treat offers a website (www.treat.com) and mobile app to complement the offering with relevant health and wellness content designed to help people on the go with information that could impact their travel. The platform provides travelers access to a comprehensive online marketplace of services including global illness tracker tools such as the COVID-19 Requirements Map, on-demand chat care by licensed providers, a health wallet to store personal and family health records (including COVID-19 testing results), and a scheduler to arrange for direct care at one of the Company’s on-site locations. <span style="background:#ffffff;">The information on the Treat website is not incorporated by reference into this Quarterly Report on Form 10-Q and does not constitute a part of this Form 10-Q.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">HyperPointe Acquisition</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In January 2022, the Company announced and closed on the acquisition of gcg Connect, LLC d/b/a HyperPointe.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The purchase price in the transaction consisted of $7,121 in cash and $906 in common stock, offset by the settlement of intercompany accounts payable of $770 as well as potential additional earn-out payments of up to $7,500 over a three-year timeframe based upon future performance; these earn-out payments may be satisfied in cash or common stock or a combination thereof subject to various terms and conditions. As of the acquisition date, and as of March 31, 2022, the Company believes that the fair value of the potential earnout payment is $0. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">HyperPointe currently operates as a new operating segment within the XpresSpa Group. The chief executive officer of HyperPointe before the Company’s acquisition, continues to serve as the chief executive officer of HyperPointe, as well as serving as the chief executive officer of XpresCheck.  See <i style="font-style:italic;">Note 7. Acquisition of HyperPointe</i> for related discussion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liquidity and Financial Condition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of March 31, 2022, the Company had cash and cash equivalents, excluding restricted cash, of $82,990, total current assets of $88,463, total current liabilities of $18,648 and positive working capital of $69,815, compared to a positive working capital of $89,152 as of December 31, 2021.</p>
CY2022Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
4
CY2021 xspa Revenue Contract Amount Not Yet Recognized
RevenueContractAmountNotYetRecognized
2001000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
82990000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
88463000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
18648000
CY2022Q1 xspa Working Capital
WorkingCapital
69815000
CY2021Q4 xspa Working Capital
WorkingCapital
89152000
CY2022Q1 us-gaap Cash
Cash
80096000
CY2022Q1 xspa Net Loss Attributable To Common Shareholders
NetLossAttributableToCommonShareholders
-4283000
CY2021Q1 xspa Net Loss Attributable To Common Shareholders
NetLossAttributableToCommonShareholders
-1056000
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
101601913
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
101058500
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
33890448
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
41116250
CY2022Q1 xspa Cash Held In Overseas Accounts
CashHeldInOverseasAccounts
2624000
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
1383000
CY2021Q4 xspa Cash Held In Overseas Accounts
CashHeldInOverseasAccounts
2113000
CY2022Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
7519000
CY2022Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2314000
CY2022Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
5205000
CY2021Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
5341000
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1609000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3732000
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1509000
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1404000
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
345000
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
283000
CY2022Q1 xspa Finite Lived Intangible Assets Amortization Expense After Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour
281000
CY2022Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
5205000
CY2021Q4 us-gaap Cash
Cash
102560000
CY2022Q1 xspa Currency Other Than Us Dollars
CurrencyOtherThanUsDollars
2624000
CY2021Q4 xspa Currency Other Than Us Dollars
CurrencyOtherThanUsDollars
2133000
CY2022Q1 us-gaap Restricted Cash
RestrictedCash
751000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
751000
CY2022Q1 us-gaap Credit And Debit Card Receivables At Carrying Value
CreditAndDebitCardReceivablesAtCarryingValue
270000
CY2021Q4 us-gaap Credit And Debit Card Receivables At Carrying Value
CreditAndDebitCardReceivablesAtCarryingValue
813000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
83741000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
106257000
CY2022Q1 us-gaap Time Deposits At Or Above Fdic Insurance Limit
TimeDepositsAtOrAboveFDICInsuranceLimit
78917000
CY2021Q4 us-gaap Time Deposits At Or Above Fdic Insurance Limit
TimeDepositsAtOrAboveFDICInsuranceLimit
103339000
CY2022Q1 xspa Amortization And Impairment Of Intangible Assets
AmortizationAndImpairmentOfIntangibleAssets
393000
CY2021Q1 xspa Amortization And Impairment Of Intangible Assets
AmortizationAndImpairmentOfIntangibleAssets
99000
CY2022Q1 xspa Lease Concessions
LeaseConcessions
321000
CY2021Q1 xspa Lease Concessions
LeaseConcessions
472000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
1010000
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
1073000
CY2022Q1 xspa Right Of Use Asset Obtained In Exchange For New And Modified Operating Lease Liability
RightOfUseAssetObtainedInExchangeForNewAndModifiedOperatingLeaseLiability
-305000
CY2021Q1 xspa Right Of Use Asset Obtained In Exchange For New And Modified Operating Lease Liability
RightOfUseAssetObtainedInExchangeForNewAndModifiedOperatingLeaseLiability
-325000
CY2021Q1 xspa Right Of Use Asset Surrendered In Exchange For Termination Of Operating Lease Liability
RightOfUseAssetSurrenderedInExchangeForTerminationOfOperatingLeaseLiability
9000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
2746000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2890000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2150000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1572000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
764000
CY2022Q1 xspa Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
1074000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
11196000
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1062000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
10134000
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y18D
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.100
CY2022Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
271000
CY2021Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
150000
CY2022Q1 us-gaap Variable Lease Payment
VariableLeasePayment
364000
CY2021Q1 us-gaap Variable Lease Payment
VariableLeasePayment
97000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.56
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
56880
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
1.90
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
1667
CY2022Q1 xspa Share Based Compensation Arrangement By Share Based Payment Award Vested Options Expired Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedOptionsExpiredWeightedAverageGrantDateFairValue
1.53
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4062699
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
2.26
CY2022Q1 us-gaap Unsecured Debt Current
UnsecuredDebtCurrent
1433000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1829142
CY2021Q4 us-gaap Unsecured Debt Current
UnsecuredDebtCurrent
3584000
CY2022Q1 us-gaap Long Term Debt
LongTermDebt
1433000
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
3584000
CY2022Q1 xspa Number Of Equal Quarterly Vesting Installment
NumberOfEqualQuarterlyVestingInstallment
4
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2826871
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
2.57
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1294375
CY2022Q1 xspa Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageGrantDateFairValue
2.90
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1543000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1005000
CY2022Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
4
CY2022Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
4
CY2022Q1 us-gaap Revenues
Revenues
24048000
CY2021Q1 us-gaap Revenues
Revenues
8512000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2451000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-921000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1264000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
744000
CY2022Q1 xspa Property Plant Equipment Capital Expenditure
PropertyPlantEquipmentCapitalExpenditure
2665000
CY2021Q1 xspa Property Plant Equipment Capital Expenditure
PropertyPlantEquipmentCapitalExpenditure
964000
CY2022Q1 xspa Long Lived Assets
LongLivedAssets
15752000
CY2021Q1 xspa Long Lived Assets
LongLivedAssets
11156000
CY2022Q1 us-gaap Assets
Assets
113738000
CY2021Q1 us-gaap Assets
Assets
119820000

Files In Submission

Name View Source Status
0001558370-22-008969-index-headers.html Edgar Link pending
0001558370-22-008969-index.html Edgar Link pending
0001558370-22-008969.txt Edgar Link pending
0001558370-22-008969-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
xspa-20220331.xsd Edgar Link pending
xspa-20220331x10q.htm Edgar Link pending
xspa-20220331x10q_htm.xml Edgar Link completed
xspa-20220331xex31d1.htm Edgar Link pending
xspa-20220331xex31d2.htm Edgar Link pending
xspa-20220331xex32.htm Edgar Link pending
xspa-20220331_cal.xml Edgar Link unprocessable
xspa-20220331_def.xml Edgar Link unprocessable
xspa-20220331_lab.xml Edgar Link unprocessable
xspa-20220331_pre.xml Edgar Link unprocessable